ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2012

Abstract Number: 44

Inhibition of WNT Signaling Pathway by Sclerostin Maintains Cartilage Homeostasis

Wafa Bouaziz1, Thomas Funck-Brentano1, Hilene Lin1, Eric Hay1 and Martine Cohen-Solal2, 1INSERM U606 Paris 7 university, Paris, France, 2Rhumatologie A, INSERM U606 Hôpital Lariboisière, Centre Viggo Petersen, Paris, France

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2012

Keywords: bone metabolism, cartilage and chondrocytes, OA

Session Information

Title: Biology and Pathology of Bone and Joint

Session Type: Abstract Submissions (ACR)

Background/Purpose: Cartilage homeostasis is regulated by several mechanisms that influence the anabolic and catabolic tissue balance. Among them, the local activation of Wnt signaling pathway plays a major role in chondrocyte metabolism. Sclerostin, a Wnt inhibitor mainly produced by osteocytes, might regulate chondrocyte differentiation. Therefore, we aim to assess the role of Sclerostin in chondrocyte maintenance.

Methods: Primary murine chondrocytes, isolated from long bone epiphysis of 6 day-old mice, were cultured with or without Wnt3a and in the presence or absence of mouse recombinant Sclerostin (20ng/ml). Proteoglycan release induced by Wnt was quantified in the supernatant of chondrocytes by a colorimetric assay. Activation of the Wnt pathway was analyzed by the translocation of β-catenin (IF, TOP-GAL activity). Chondrocyte proliferation and apoptosis were investigated by BrdU and Tunel assays. The mRNA gene expression of anabolic and catabolic genes was quantified by RT-qPCR. We assessed the expression of Sclerostin in normal and osteoarthritic cartilage in mice with joint instability induced by partial meniscectomy (immunohistochemistry).

Results: The proteoglycan amount released in the chondrocyte culture supernatants was reduced by Wnt while it was rescued in the presence of Sclerostin. Wnt inhibited the gene expression of collagen type II (X18-fold), Sox9 (X140 fold) and Aggrecan (X90-fold) and increased the gene expression of metalloproteinases such as Adamts-4 (X5-fold), Adamts-5 (X5.5-fold), MMP3 (X7-fold) and MMP13 (X6.6-fold). In contrast, Sclerostin significantly prevented the increase of the catabolic genes induced by Wnt (X1.7-fold Adamts-4, X1.6-fold Adamts-5, X3.4-fold MMP3 and X4-fold  MMP13) and rescued partially the expression of the anabolic genes (X5- fold collagen type II, X6-fold Sox-9 and X11-fold Aggrecan). Furthermore, Wnt enhanced the gene expression of collagen type X (X3-fold) which was abolished by Sclerostin (X1.6-fold). However, Sclerostin failed to exert any effect on the proliferation or the apoptosis of chondrocytes regardless of the presence of Wnt. Finally, we found that Sclerostin is expressed only in the calcified zone of the normal articular cartilage and this is increased after meniscectomy, suggesting that Sclerostin might participate to cartilage damage.

Conclusion: Herein, we showed that the inhibition of Wnt/β-catenin pathway by Sclerostin preserves chondrocyte maintenance by inhibiting chondrocyte catabolism and hypertrophy. These results further indicate the importance of Wnt antagonists in targeting cartilage degradation in OA.


Disclosure:

W. Bouaziz,
None;

T. Funck-Brentano,
None;

H. Lin,
None;

E. Hay,
None;

M. Cohen-Solal,
None.

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inhibition-of-wnt-signaling-pathway-by-sclerostin-maintains-cartilage-homeostasis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology